C4 therapeutics appoints leonard reyno, m.d., as chief medical officer

Watertown, mass., june 20, 2023 (globe newswire) -- c4 therapeutics, inc. (c4t) (nasdaq: cccc), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today announced the appointment of leonard (len) reyno, m.d., as chief medical officer, effective july 10, 2023. dr. reyno is a seasoned biotech executive with nearly 30 years of clinical development experience, spanning first-in-human studies to phase iv clinical trials. at c4t, dr. reyno will be responsible for driving c4t's clinical strategy to advance its promising pipeline of degrader therapies.
CCCC Ratings Summary
CCCC Quant Ranking